Cytokinetics insiders, including CEO, sell significant shares amid stock trading below moving averages.

Cytokinetics' CEO Robert I. Blum and other executives have recently sold large amounts of company stock, with Blum selling nearly 105,000 shares in total, including a major block under a pre-arranged trading plan. This insider selling occurs while the company's stock trades below both its 50-day and 200-day moving averages, despite the 50-day average being higher. Cytokinetics remains unprofitable with a negative P/E ratio, signaling challenges ahead. Insider sales may indicate cautious sentiment about the company's near-term prospects.

Following the insider selling by Cytokinetics' CEO and executives, the company's stock price on Pluang is currently USD 64.77 as of Sep 29, 2026 21:47 WIB, down 2.10% for the day. The stock trades below its 52-week high of USD 87.26 and above its 52-week low of USD 53.89, with a market cap of $9.20 billion. Typical hold time for CYTK on Pluang is 19 days, indicating relatively short-term investor interest.